• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1707147-26-9 (THK5351)

1

Identification

THK5351 THK5351
Name THK5351
Formula C18H18FN3O2
MW 0.0
CAS No. 1707147-26-9
EINECS
Smiles O[[email protected]@H](COC1=CC=C2N=C(C3=CC=C(NC)N=C3)C=CC2=C1)CF
Synonyms THK-5351;THK 5351; (S)-1-fluoro-3-((2-(6-(methylamino)pyridin-3-yl)quinolin-6-yl)oxy)propan-2-ol
InChI InChI=1S/C18H18FN3O2/c1-20-18-7-3-13(10-21-18)17-5-2-12-8-15(4-6-16(12)22-17)24-11-14(23)9-19/h2-8,10,14,23H,9,11H2,1H3,(H,20,21)/t14-/m1/s1
2

Introduction

THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

Background Information

THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000124223

Storage condition

Solubility

DMSO by CHEMSCENE, LLC
DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
THK5351 Chang Gung Memorial Hospital Alzheimer's Disease 2015/12/1 Phase 1
THK5351 Asan Foundation Alzheimer Disease 2017/5/17 Phase 1
THK5351 Jae Seung Kim|Korea Health Industry Development Institute|Samsung Medical Center|Asan Medical Center Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases 2016/1/1 Phase 2
THK5351 Columbia University|National Institute on Aging (NIA) Diabetes Mellitus|Alzheimer Dementia 2017/6/1 Phase 2
7

Safety Data of THK5351

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
CHEMSCENE, LLC 1mg/USD180();5mg/USD540() USA
MedChemexpress Co., Ltd. 1mg/USD180();5mg/USD540() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 1mg/USD180();5mg/USD540() China
10

Related Products

Other Forms of 1707147-26-9

Name CAS No Formula MW

Recommended Compounds in Others

Name CAS No Formula MW
(R)-(+)-Etomoxir (sodium salt) 828934-41-4 C15H18ClNaO4 320.74
Dictamine 484-29-7 C12H9NO2 199.21
3,3',5-Triiodo-L-thyronine (sodium) 55-06-1 C15H11I3NNaO4 672.9553
Fabomotizole (hydrochloride) 173352-39-1 C15H22ClN3O2S 343.8721
FPH2 957485-64-2 C14H16ClN5O2S 353.83
α-Tocopherol (phosphate) 38976-17-9 C29H51O5P 510.69
BAMB-4 891025-25-5 C15H12N2O2 252.27
LDN-27219 312946-37-5 C20H16N4O2S2 408.5
ISO-1 478336-92-4 C12H13NO4 235.24
Aurothioglucose 12192-57-3 C6H11AuO5S 392.18
Oxybenzone 131-57-7 C14H12O3 228.24
ITX3 347323-96-0 C22H17N3OS 371.45
Cardiogreen 3599-32-4 C43H47N2NaO6S2 774.96
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 465.34
INH1 313553-47-8 C18H16N2OS 308.4
PF6-AM 1268491-69-5 C33H31BO12 630.4
XEN445 1515856-92-4 C18H17F3N2O3 366.33
Disperse Blue 148 52239-04-0 C19H19N5O4S 413.45026
Solvent Blue 35 17354-14-2 C22H26N2O2 350.454
CID-797718 370586-05-3 C12H11NO3 217.2206

Recommended Compounds in Same Indication

Name CAS No Formula MW
CHF5074 749269-83-8 C16H11Cl2FO2 325.1617
Azeliragon 603148-36-3 C32H38ClN3O2 532.116
LY451395 375345-95-2 C21H30N2O4S2 438.6
GTS-21 148372-04-7 C19H20N2O2 308.37
GTS-21 (dihydrochloride) 156223-05-1 C19H22Cl2N2O2 381.3
VITAMIN K1 12001-79-5 C31H46O2 450.7
T807 1415379-56-4 C16H10FN3 0.0
MSDC 0160 146062-49-9 C19H18N2O4S 370.42
Scopolamine 51-34-3 C17H21NO4 303.35
MK-0249 862309-06-6 C23H24F3N3O2 431.45
11

Route of Synthesis

12

References

13

More Information

THK5351

Tags: buy 1707147-26-9 IC50 | 1707147-26-9 price | 1707147-26-9 cost | 1707147-26-9 solubility | 1707147-26-9 purchase | 1707147-26-9 manufacturer | 1707147-26-9 research buy | 1707147-26-9 order | 1707147-26-9 MSDS | 1707147-26-9 chemical structure | 1707147-26-9 Storage condition | 1707147-26-9 molecular weight | 1707147-26-9 mw | 1707147-26-9 datasheet | 1707147-26-9 supplier | 1707147-26-9 cell line | 1707147-26-9 NMR | 1707147-26-9 MS | 1707147-26-9 IR | 1707147-26-9 solubility | 1707147-26-9 Safe information | 1707147-26-9 Qc and Spectral Information | 1707147-26-9 Clinical Information | 1707147-26-9 Clinical Trial | 1707147-26-9 Route of Synthesis | 1707147-26-9 storage condition | 1707147-26-9 diseases and conditions | 1707147-26-9 flash point | 1707147-26-9 boiling point | 1707147-26-9 melting point | 1707147-26-9 storage condition | 1707147-26-9 brand